We came across a bullish thesis on Zenas BioPharma, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ZBIO. Zenas BioPharma, Inc.’s share was trading at $27.02 as of February 19th. ZBIO’s trailing P/E was 1.93 according to Yahoo Finance.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. ZBIO is transitioning...
